News Zydus Lifesciences Limited

Equities

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 06:49:34 2025-01-15 am EST			5-day change	1st Jan Change
984.90 ^INR	-1.52%		-1.59%	+1.36%

Jan. 10	Nomura Upgrades Zydus Lifesciences to Buy From Neutral, Adjusts Price Target to INR1,140 From INR1,030	MT
Jan. 07	CVS Health Unit to Include Zydus Lifesciences' Diabetes Medications in Template Formulary	MT

Nomura Upgrades Zydus Lifesciences to Buy From Neutral, Adjusts Price Target to INR1,140 From INR1,030	Jan. 10	MT
Zydus announces agreement with CVS Caremark to add ZituvioTM, ZituvimetTM andZituvimetTM XR to its template formulary	Jan. 08	AQ
CVS Health Unit to Include Zydus Lifesciences' Diabetes Medications in Template Formulary	Jan. 07	MT
Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 Product Candidate for Treatment of Menkes Disease	Jan. 07	AQ
Zydus Announces Agreement with CVS Caremark to Add Zituvio Tm, Zituvimettm and Zituvimettm XR (Sitagliptin \| Sitagliptin and Metformin Hydrochloride) to Its Template Formulary	Jan. 06	CI
Zydus Lifesciences Limited Appoints Vikram Shukla as a President-Parenteral Operations	Jan. 03	CI
Zydus Lifesciences Gets Final Approval from US FDA for Lidocaine and Prilocaine Cream	Dec. 19	MT
Zydus Lifesciences Limited Receives Final Approval from USFDA for Lidocaine and Prilocaine Cream USP, 2.5%/2.5%	Dec. 19	CI
Zydus Lifesciences Limited Receives Demand Order-In-Original from Assistant Commissioner, Division Dehradun, Sector-7, Uttarakhand	Nov. 28	CI
Nomura Adjusts Zydus Lifesciences' Price Target to INR1,030 From INR1,020, Keeps at Neutral	Nov. 14	MT
Jefferies Adjusts Zydus Lifesciences' Price Target to INR1,380 From INR1,450, Keeps at Buy	Nov. 13	MT
Zydus Lifesciences Posts Gains in Fiscal Q2 Consolidated Net Profit	Nov. 13	MT
Zydus Lifesciences Limited, Q2 2025 Earnings Call, Nov 12, 2024	Nov. 12
India's Zydus Life posts Q2 profit rise on steady US demand	Nov. 12	RE
Zydus Lifesciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	Nov. 12	CI
Zydus Lifesciences Limited Receives in Principle Acceptability from World Health Organization for Zyvac Tcv	24-10-23	CI
Zydus Lifesciences Limited Receives Final Approval from USFDA for Fludrocortisone Acetate Tablets USP, 0.1 Mg	24-10-17	CI
Zydus Lifesciences to Start Phase 2 Trials of Desidustat for Sickle Cell Disease	24-10-14	MT
Zydus Lifesciences Limited and ICMR Initiate A Phase 2 Proof-Of-Concept Trial of Desidustat in Patients with Sickle Cell Disease	24-10-14	CI
Zydus Lifesciences Limited Receives Final Approval from USFDA for Paliperidone Extended-Release Tablets	24-10-10	CI
Zydus Lifesciences Gets Tentative Nod from US FDA for Enzalutamide Tablets	24-10-02	MT
Zydus Receives Tentative Approval from USFDA for Enzalutamide Tablets, 40 Mg and 80 Mg	24-10-02	CI
Zydus Lifesciences Limited Receives Final Approval from USFDA for Enzalutamide Capsules, 40 Mg	24-09-28	CI
Zydus Lifesciences Limited and CSIR-Central Drug Research Institute Lucknow to Develop Best-In-Class Drug for Chronic Kidney Disease Induced Osteoporosis	24-09-27	CI
Zydus Lifesciences to Acquire Active Pharmaceutical Ingredients Business of Sterling Biotech	24-09-17	MT

Become a member to access more news.

100% Free Registration

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Zydus Lifesciences Limited

Equities

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Filters